[Laboratory and clinical studies of XXXX in the pediatric field].

@entity1 @entity796 @entity3274 @entity5647 @entity5646 @entity526
The authors have carried out the laboratory and clinical studies of @entity5646 ( @entity5647 ) and obtained the following results. The antibacterial activities of @entity5647 against the clinical isolates of @entity526 , K. pneumoniae and @entity796 were measured by the agar dilution method with inoculum size of 10(6) cells/ml. The susceptibility distribution of @entity526 to @entity5647 ranged from 0.025 or lower to 1.56 microgram/ml, and the peak of distribution was 0.05 microgram/ml. The peak of susceptibility distribution of @entity3274 was 0.025 microgram/ml or lower, and the distribution of @entity796 ranged from 0.1 to 100 micrograms/ml higher and the peak of distribution was 3.13 micrograms/ml. After intravenous bolus injection of 20 mg of @entity5647 in 4 @entity1 , the mean peak serum level was 117 +/- 35.1 micrograms/ml at 15 minutes after injection, and half-life time was 1.42 hours. The mean urinary excretion rates was 63.2 +/- 30.6% up to 6 hours after bolus injection of 20 mg/kg of @entity5647 . @entity5647 was given 11 cases with bacterial injection. Daily doses of @entity5647 were from 41.7 to 94.9 mg/kg. Clinical results obtained were excellent and good responses in 8 of 11 cases (72.7%). No side effect was observed.
